Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.32 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916379 | 0.86 | TTR (0.41) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL14689467 | 0.86 | TTR (0.41) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL27902180 | 0.83 | MEN1 (0.38) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL9948485 | 0.81 | CYP2A6 (0.48) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL1363861 | 0.81 | LOXL2 (0.48) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL2161079 | 0.81 | TTR (0.43) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL504640 | 0.78 | TTR (0.52) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL200313 | 0.78 | TTR (0.52) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL19442430 | 0.78 | LOXL2 (0.52) | TTRALBMEN1KMT2ACYP2A6 | |
| SCHEMBL19440748 | 0.78 | MEN1 (0.36) | TTRALBMEN1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591351-B | Polycyclic compound and preparation method and application thereof | 成都科岭源医药技术有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-115960094-A | Preparation and application of aromatic ring substituted methylamine derivative | 上海璎黎药业有限公司 | 2023-04-14 | — | — | CN | disclosed |
| WO-2022117090-A1 | POLYCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都科岭源医药技术有限公司 | 2022-06-09 | — | — | WO | disclosed |
| CN-114591351-A | Polycyclic compound and preparation method and application thereof | 成都科岭源医药技术有限公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2020185755-A1 | TYK2 INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| EP-3176172-B1 | SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2020-01-29 | — | — | EP | disclosed |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2019-03-19 | — | — | US | disclosed |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2018-08-09 | — | — | US | disclosed |
| US-9918985-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-03-20 | — | — | US | disclosed |
| US-20170319578-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-09 | — | — | US | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009100170-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100170-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100169-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100169-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE4B, PDE1A | TTR 4826/4885ALB 4728/4885MEN1 4113/4885 |
| US-10231967-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | TTR 756/4885ALB 2213/4885MEN1 2593/4885 |
| US-20180221367-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | TTR 756/4885ALB 2213/4885MEN1 2593/4885 |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4B, PDE4A, CHRM4 | TTR 4699/4885ALB 4592/4885MEN1 3908/4885 |
| US-20170319578-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | TTR 756/4885ALB 2213/4885MEN1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.